Clinical Toxicology is the study of agents that cause toxic or adverse effects to the body. This sub-field usually deals with the side effects of drugs or chemicals given to a patient in order to treat other symptoms or diseases.
Over the past 25 years surgically dependent animal models have expanded from a small, almost niche area in pharmaceutical research to an important component of most research portfolios. In t...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, b...
Multiplexing IHC is a technique that is increasing in demand as more and more researchers and physicians are being tasked with doing more with less. With multiplexing, you have the advantage...
Second harmonic generation (SHG) is a biophysical method that sensitively measures real-time conformational change of biomolecules attached to membranes. SHG has recently been applied to dete...
The Chain of Custody in our labs is the unbroken link between the objects used in your research: your people, the animal models, the cell lines, reagents, compounds; the lab instruments and d...
Ageing is a complex process that has been observed in all biological systems at every level of organisation. Some anti-ageing interventions have demonstrated life-extending effects in model o...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
Pharmaceutical research and development efforts are often both inefficient and suffer from a high attrition rate of drug candidates within the clinical phase of development. Most drug t...
The lung is a highly complex organ, comprised of more than 40 cell types that are responsible for various important functions, the lung’s complexity contributes to the subsequent challe...
This presentation will discuss and review the promise and potential of 3D Microtissues, and the challenges of using these Microtissues as Hazard ID tools. Lastly, we will discuss the potentia...
The goal of transforming one’s pipeline to a steady source of usable data is within our reach. Data that could be used for clinical insights or earlier in the drug discovery process. &n...
Experimental models that promise to replace animal tests that are currently required for drugs and chemicals are rapidly proliferating. This includes a number of novel solutions offered by bi...
Comparative oncology is the study of naturally-occurring cancers in pet animals (mainly dogs) to broaden and deepen our collective understanding of cancers in both companion species and human...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
As we look towards data to help generate insight and analytics across the entire drug discovery value chain, learn how interconnected data is from the various stages of preclinical, clinical,...
Preclinical drug discovery is at the edge of a major transformation that promises to improve translation to the clinic through enhanced acquisition and advanced analysis of data. While an imp...
Animal welfare is the most important issue in any in vivo laboratory. The ability to detect and intervene in cases where the conditions of animals may be deteriorating as well as the ability...
Xenobiotic-induced cardiotoxicity is a major concern for both pharmaceuticals and chemicals in the marketplace. For drugs, "Thorough QT/corrected QT (QTc)" (TQT) studies are corners...
A collection of opinions, questions and other assorted thoughts about the intersection of these developing technologies and preclinical studies primarily focused on the early discovery (as op...
In biomedical research, data should be treated as first-class corporate assets--they were expensive to create, they are expensive to maintain, and they have future business value. The petabyt...
Digitalization has transformed virtually every industry, but it has been slow to gain traction within the preclinical phase of the drug development journey. Recent advances in digital vivariu...
The printing press, the automobile & the Internet are just a few technological achievements that have advanced our world. All were driven by human ingenuity: our innate creativity that in...
Over the past 25 years surgically dependent animal models have expanded from a small, almost niche area in pharmaceutical research to an important component of most research portfolios. In t...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, b...
Multiplexing IHC is a technique that is increasing in demand as more and more researchers and physicians are being tasked with doing more with less. With multiplexing, you have the advantage...
Second harmonic generation (SHG) is a biophysical method that sensitively measures real-time conformational change of biomolecules attached to membranes. SHG has recently been applied to dete...
The Chain of Custody in our labs is the unbroken link between the objects used in your research: your people, the animal models, the cell lines, reagents, compounds; the lab instruments and d...
Ageing is a complex process that has been observed in all biological systems at every level of organisation. Some anti-ageing interventions have demonstrated life-extending effects in model o...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
Pharmaceutical research and development efforts are often both inefficient and suffer from a high attrition rate of drug candidates within the clinical phase of development. Most drug t...
The lung is a highly complex organ, comprised of more than 40 cell types that are responsible for various important functions, the lung’s complexity contributes to the subsequent challe...
This presentation will discuss and review the promise and potential of 3D Microtissues, and the challenges of using these Microtissues as Hazard ID tools. Lastly, we will discuss the potentia...
The goal of transforming one’s pipeline to a steady source of usable data is within our reach. Data that could be used for clinical insights or earlier in the drug discovery process. &n...
Experimental models that promise to replace animal tests that are currently required for drugs and chemicals are rapidly proliferating. This includes a number of novel solutions offered by bi...
Comparative oncology is the study of naturally-occurring cancers in pet animals (mainly dogs) to broaden and deepen our collective understanding of cancers in both companion species and human...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
As we look towards data to help generate insight and analytics across the entire drug discovery value chain, learn how interconnected data is from the various stages of preclinical, clinical,...
Preclinical drug discovery is at the edge of a major transformation that promises to improve translation to the clinic through enhanced acquisition and advanced analysis of data. While an imp...
Animal welfare is the most important issue in any in vivo laboratory. The ability to detect and intervene in cases where the conditions of animals may be deteriorating as well as the ability...
Xenobiotic-induced cardiotoxicity is a major concern for both pharmaceuticals and chemicals in the marketplace. For drugs, "Thorough QT/corrected QT (QTc)" (TQT) studies are corners...
A collection of opinions, questions and other assorted thoughts about the intersection of these developing technologies and preclinical studies primarily focused on the early discovery (as op...
In biomedical research, data should be treated as first-class corporate assets--they were expensive to create, they are expensive to maintain, and they have future business value. The petabyt...
Digitalization has transformed virtually every industry, but it has been slow to gain traction within the preclinical phase of the drug development journey. Recent advances in digital vivariu...
The printing press, the automobile & the Internet are just a few technological achievements that have advanced our world. All were driven by human ingenuity: our innate creativity that in...
Follow
